Francisco Andújar Vera
Biography
|
Francisco Andújar Vera is a bioinformatics researcher at the Instituto de Salud Carlos III (CIBERFES) in Granada since 2022. From 2017 to 2022 he worked as a bioinformatician at FIBAO (Fundación para la Investigación Biosanitaria de Andalucía Oriental), and from 2012 to 2015 as a senior laboratory technician at VIRCELL S.L., developing PCR controls. (Description curated from publicly available data.) |
Profile
| Institution | ISCIII |
| Position | Bioinformatics Researcher, CIBERFES |
| Home page | https://www.linkedin.com/in/francisco-and%C3%BAjar-vera-b3104b120/ |
| Contact email | fandujar@fibao.es |
| ORCID | 0000-0002-2663-8809 |
BCB Hub
| BCB Committee | Not a member |
| BCB Tools | |
| BCB Services |
Research
Research topics
Data AnalysisMachine Learning in BiologyGenomicsDNA methylationMutation Analysis and designMetabolomicsNetwork BiologyClinical dataMedicine
Research lines
None
Publications 20 entries
- Alkaline Phosphatase as a Potential Biomarker of Muscle Function: A Pilot Study in Patients with Hypophosphatasia Article · 26 Jun 2025
- N-acetyltransferase Gene Variants Involved in Pediatric Idiosyncratic Drug-Induced Liver Injury Article · 11 Jun 2024
- Cardioprotective function of sclerostin by reducing calcium deposition, proliferation, and apoptosis in human vascular smooth muscle cells Article · 2 Nov 2023
- Exploring the role of osteoglycin in type 2 diabetes: implications for insulin resistance and vascular pathophysiology Article · 1 Nov 2023
- Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM Article · 1 Sep 2023
View all (15 more)
- Mild hypophosphatasia may be twice as prevalent as previously estimated: an effective clinical algorithm to detect undiagnosed cases Article · 14 Jul 2023
- Analysis of the Genetic Relationship between Atherosclerosis and Non-Alcoholic Fatty Liver Disease through Biological Interaction Networks Article · 18 Feb 2023
- Exploring the Role of Sclerostin as a Biomarker of Cardiovascular Disease and Mortality: A Scoping Review Article · 30 Nov 2022
- Undercarboxylated Osteocalcin: A Promising Target for Early Diagnosis of Cardiovascular and Glycemic Disorders in Patients with Metabolic Syndrome: A Pilot Study Article · 21 Jul 2022
- The Contribution of Wnt Signaling to Vascular Complications in Type 2 Diabetes Mellitus Article · 23 Jun 2022
- Characterization of Genetic Variants of Uncertain Significance for the ALPL Gene in Patients With Adult Hypophosphatasia Article · 14 Apr 2022
- Identification of Potential Targets Linked to the Cardiovascular/Alzheimer’s Axis through Bioinformatics Approaches Article · 6 Feb 2022
- Lower trabecular bone score in type 2 diabetes mellitus: A role for fat mass and insulin resistance beyond hyperglycaemia Article · Nov 2021
- Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients Article · 20 May 2021
- Hypophosphatasia: A Unique Disorder of Bone Mineralization Article · 21 Apr 2021
- Association between oxidative-stress-related markers and calcified femoral artery in type 2 diabetes patients Article · Oct 2020
- Circulating Undercarboxylated Osteocalcin as Estimator of Cardiovascular and Type 2 Diabetes Risk in Metabolic Syndrome Patients Article · 4 Feb 2020
- Epidemiological, Clinical and Genetic Study of Hypophosphatasia in A Spanish Population: Identification of Two Novel Mutations in The Alpl Gene Article · 2 Jul 2019
- Usefulness of Trabecular Bone Score (TBS) to Identify Bone Fragility in Patients with Primary Hyperparathyroidism Article · Apr 2019
- Circulating levels of sclerostin are associated with cardiovascular mortality Article · 21 Jun 2018